Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (561-570 of 1,211) with videos related to

Pageof 122
Sort By:
European Heart Journal|February 4, 2017
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HFMichael Böhm, Robin Young, Pardeep S Jhund, et al.
American Journal of Nephrology|December 15, 2017
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy TrialFinnian R Mc Causland, Brian Claggett, Marc A Pfeffer, et al.
Circulation|April 30, 2019
High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC StudyXiaoming Jia, Wensheng Sun, Ron C Hoogeveen, et al.
European Journal of Heart Failure|September 19, 2018
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fractionAdriaan A Voors, Sanjiv J Shah, Jeroen J Bax, et al.
Journal of Cardiac Failure|May 23, 2023
Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF TrialJohn W Ostrominski, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trialAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
Nature Medicine|March 30, 2026
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trialScott D Solomon, John J V McMurray, G Michael Felker, et al.
Circulation|December 7, 2023
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical TrialsJohn J V McMurray, Kieran F Docherty, Rudolf A de Boer, et al.
Journal of the American College of Cardiology|April 22, 2022
Association of Left Atrial Structure and Function With Heart Failure in Older AdultsRiccardo M Inciardi, Brian Claggett, Masatoshi Minamisawa, et al.
European Journal of Heart Failure|April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programmeSu Min Chang, Christopher B Granger, Peter A Johansson, et al.
Pageof 122

Showing results (561-570 of 1,211) with videos related to

Sort By:
Pageof 122
European Heart Journal|February 4, 2017
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HFMichael Böhm, Robin Young, Pardeep S Jhund, et al.
American Journal of Nephrology|December 15, 2017
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy TrialFinnian R Mc Causland, Brian Claggett, Marc A Pfeffer, et al.
Circulation|April 30, 2019
High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC StudyXiaoming Jia, Wensheng Sun, Ron C Hoogeveen, et al.
European Journal of Heart Failure|September 19, 2018
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fractionAdriaan A Voors, Sanjiv J Shah, Jeroen J Bax, et al.
Journal of Cardiac Failure|May 23, 2023
Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF TrialJohn W Ostrominski, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trialAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
Nature Medicine|March 30, 2026
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trialScott D Solomon, John J V McMurray, G Michael Felker, et al.
Circulation|December 7, 2023
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical TrialsJohn J V McMurray, Kieran F Docherty, Rudolf A de Boer, et al.
Journal of the American College of Cardiology|April 22, 2022
Association of Left Atrial Structure and Function With Heart Failure in Older AdultsRiccardo M Inciardi, Brian Claggett, Masatoshi Minamisawa, et al.
European Journal of Heart Failure|April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programmeSu Min Chang, Christopher B Granger, Peter A Johansson, et al.
Pageof 122